Genomic epidemiology of campylobacter to improve disease control in low and middle income countries

Active Project Grant Awarded Last action

Award ID
R01AI158576
Recipient
Awarding agency
Obligated
$8,535,391

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 94% complete
Originally
Funding
  • $7,796,958.00 Federal
  • $738,433.00 Non-federal
Place of performance
Charlottesville, VA 22904, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Campylobacter is among the principal causes of bacterial enteritis worldwide and the progressive development of antimicrobial resistance among global isolates, particularly in low and middle income countries, has led the CDC to list drug-resistant campylobacter at the top of its list of serious threats in 2019. In the past decade in europe major investments in genomic epidemiology have informed successful interventions to decrease rates of human infection and sequelae such as guillan-barre syndrome. Despite clear evidence that campylobacter is a principal cause of enteritis in the developing world, advanced approaches in source attribution have not been employed to identify the principal sources of infection causing disease in humans, or to identify the sources of human infections resistant to both fluoroquinolones and azithromycin (MDR campylobacter), despite their documented high incidence. The limited genomic study of campylobacter done in low and middle income countries demonstrates important differences in the genomes of isolates from both humans and zoonotic sources, indicating that transmission dynamics differ in these settings compared to that seen in high income countries. The current deficit in accurate quantitative source attribution to zoonotic source populations where most infections occur is a critical knowledge GAP in the global control of campylobacter infections. The objective of this project is to inform targeted disease control measures to reduce the impact of campylobacteriosis and human MDR campylobacter in low and middle income countries. Our central hypothesis is that industrially produced meat products are the principal source of campyobacteriosis and MDR campylobacter in humans in this population. In order to test our central hypothesis we will 1) identify host segregating features of campylobacter from zoonotic sources in peru; 2) characterize genomes of campylobacter strains that cause disease in humans, evaluate the risk of household peron-to-person transmission and identify microbial genomic features associated with persistent asymptomatic human carriage and 3) estimate the burden of campylobacteriosis and human MDR infections attributable to domestic and industrially derived zoonotic sources. The proposed project will unite a highly complementary group of accomplished researchers with expertise in epidemiology, campylobacter genomics, bioinformatics and microbial ecology to inform strategic and targeted disease control interventions for campylobacter control in an area with one of the highest documented rates of human MDR campylobacter infection. The project is innovative in its approach to link characterized human cases and zoonotic reservoirs in a high burden lmic setting to local, regional, and global reference genomes to create robust evidence to drive policy and practice to improve the control of campylobacteriosis and the diminish the geographic expansion of MDR campylobacter.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $618,319 $0
Amendment $618,319 $0
Amendment $618,319 $0
Amendment $619,126 $0
Amendment $619,126 $0
Amendment $637,037 $0
Amendment $637,037 $0
Amendment $637,037 $0
Amendment $657,886 $0
Amendment $657,886 $0
Amendment $738,433 $0
Original award $738,433 $738,433
Show all 15

Subawards

Subrecipient Amount Awarded
Universidad Peruana Cayetano Heredia Dr. Francesca Schiaffino will be a co-I on the grant. Dr. Schiaffino will provide planning, oversite and analysis of all animal sampling, including IACUC… $101,736
University Of Oxford R01 AI158576 Scope of Work for Pascoe and Sheppard, Oxford University, UK Drs. Pascoe and Sheppard Drs. Pascoe and Sheppard will be co-investigators on the… $85,451
University Of Bath Drs. Pascoe and Sheppard will be co-investigators on the grant “Genomic epidemiology to Improve Disease Control in Low and Middle Income Countries” that will… $62,591
Agricultural Research Service Dr. Craig Parker will be a co-PI on the grant submitted by Associate Professor Margaret Kosek on the “Genomic Epidemiology of Campylobacter to Improve Disease… $193,797
Asociacion Benefica Prisma SCOPE OF WORK for AB PRISMA Asociacion Benefica PRISMA is the largest Peruvian non-governmental organization in Peru. It has a long track record in the… $871,641
University Of Arizona Scope of Work for Dr. Kerry Cooper at the University of Arizona Dr. Kerry Cooper will be a co-Investigator on the grant submitted by Associate Professor… $205,910

Quick answers

Who received award R01AI158576?

R01AI158576 was awarded to Rector & Visitors Of The University Of Virginia by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on March 15, 2021.

How much is award R01AI158576 worth?

$8,535,391 has been obligated on R01AI158576: $7,796,958 in federal funding and $738,433 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login